Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNYSE:ALR
CUSIP01449J10
Phone+1-781-6473900
Debt
Debt-to-Equity Ratio2.43
Current Ratio2.04
Quick Ratio1.54
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16.86%
Return on Equity-33.39%
Return on Assets-6.72%
Miscellaneous
Employees9,700
Outstanding Shares87,580,000
Market Cap$4.47 billion
Alere (NYSE:ALR) Frequently Asked Questions
What is Alere's stock symbol?
Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."
How were Alere's earnings last quarter?
Alere Inc (NYSE:ALR) issued its quarterly earnings data on Friday, November, 4th. The medical research company reported $0.19 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.54 by $0.35. The medical research company had revenue of $582 million for the quarter, compared to analyst estimates of $605.50 million. Alere had a negative return on equity of 33.39% and a negative net margin of 16.86%. The business's quarterly revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.10) EPS. View Alere's Earnings History.
Who are Alere's key executives?
Alere's management team includes the folowing people:
- Gregg J. Powers, Independent Chairman of the Board
- Namal Nawana, President, Chief Executive Officer, Director
- James F. Hinrichs, Chief Financial Officer, Executive Vice President
- Daniella Cramp, Global President - Cardiometabolic Business Unit
- Sanjay Malkani, Global President - Toxicology
- Avi Pelossof, Global President - Infectious Disease Business Unit
- Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
- Robert Hargadon, Senior Vice President - Global Human Resources
- John Bridgen Ph.D., Senior Vice President - Business Development
- Mark Gladwell, Senior Vice President - Global Operations
What is Alere's stock price today?
One share of ALR stock can currently be purchased for approximately $50.99.
How big of a company is Alere?
Alere has a market capitalization of $4.47 billion. Alere employs 9,700 workers across the globe.
What is Alere's official website?
How can I contact Alere?
Alere's mailing address is 51 Sawyer Rd Ste 200, WALTHAM, MA 02453-3448, United States. The medical research company can be reached via phone at +1-781-6473900.
MarketBeat Community Rating for Alere (NYSE ALR)
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe ALR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALR will underperform the S&P 500 over the long term. You may vote once every thirty days.
